ACT-335827

ACT-335827 is an orexin receptor antagonist drug that was researched and developed by Actelion. It has been studied for its potential use in the treatment of insomnia and other sleep disorders, as well as potential applications in the treatment of addiction and eating disorders.

History

ACT-335827 was developed by the Swiss pharmaceutical company Actelion. The drug is part of a class of medications known as orexin receptor antagonists, which work by blocking the action of orexin, a neurotransmitter that regulates arousal, wakefulness, and appetite.

Mechanism of Action

ACT-335827 works by selectively blocking the action of orexin, a neurotransmitter that is involved in regulating the sleep-wake cycle. By inhibiting the action of orexin, ACT-335827 may help to promote sleep and reduce wakefulness.

Clinical Trials

ACT-335827 has undergone Phase I clinical trials to evaluate its safety, tolerability, and pharmacokinetics in healthy subjects. The results of these trials have not yet been published.

Potential Applications

In addition to its potential use in the treatment of insomnia, ACT-335827 may also have applications in the treatment of addiction and eating disorders. Orexin is involved in the regulation of reward pathways in the brain, and blocking its action may help to reduce cravings and addictive behaviors.

See Also

• Orexin receptor
• Insomnia
• Addiction
• Eating disorders

References

ACT-335827 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia